China Healthcare Weekly (May.5) - Overvaluation in Primary Market, RDC to Be Hot Spot, Yiling Pharma
Only foreign markets are able to “digest” high valuation of China's biotech assets in primary market. RDC/RLT will become the next hot area for...
402 Views
Hepalink Pharma IPO: Trading Debut
Shenzhen HepaLink Pharmaceuticals (H) (HEPALINK HK) is a leading China-based pharmaceutical company with global businesses in pharmaceutical,...
410 Views
Hepalink Pharma IPO: Valuation Insights
Shenzhen HepaLink Pharmaceuticals (H) (HEPALINK HK) is a leading China-based pharmaceutical company with global businesses in pharmaceutical,...
482 Views
Falling Fertility Adds to China's Population Woes
By allowing couples to have up to two children China hopes to reverse its likely population decline. But falling fertility and the pressures of...
4.1k Views
Iran Shows China the Way on Population Expansion
Faced with dramatically falling birth rates, Iran has introduced a wide range of pro-natalist policies. In contrast, China has been half-hearted in...
211 Views